TSX gains after CPI shows US inflation rose 3%
Arcutis Biotherapeutics Inc. has reached a new 52-week high, with its stock price climbing to $21.56. The $2.57 billion market cap company demonstrates strong financial health with a current ratio of 3.2, indicating solid liquidity. According to InvestingPro data, analyst price targets range from $19 to $29. This milestone reflects significant investor interest and confidence in the company’s prospects. Over the past year, Arcutis Biotherapeutics has experienced a substantial increase in its stock value, with a remarkable 1-year change of 119.34%. The company’s impressive 89.1% gross profit margins and 99.5% revenue growth underscore its strong performance. This remarkable growth highlights the company’s potential in the biotherapeutics sector, drawing attention from both investors and analysts alike. Discover 12 additional exclusive insights and comprehensive analysis with InvestingPro’s detailed research report.
In other recent news, Arcutis Biotherapeutics has received approval from the U.S. Food and Drug Administration for its ZORYVE cream, intended for treating mild to moderate atopic dermatitis in children aged 2 to 5 years. This approval provides a non-steroid treatment option that can be used for any duration, offering a new solution for approximately 1.8 million children in the U.S. affected by this condition. Additionally, Arcutis is seeking FDA approval to expand the use of ZORYVE cream for treating plaque psoriasis in children as young as 2 years old, potentially making it the first topical PDE4 inhibitor for this age group if approved.
In another development, Mizuho has raised its price target for Arcutis Biotherapeutics to $26, maintaining an Outperform rating. This adjustment comes ahead of Arcutis’s third-quarter results and reflects an increased sales forecast for the Zoryve franchise, projected at $89 million for the third quarter of 2025. Meanwhile, Palvella Therapeutics has appointed David W. Osborne, Ph.D., a co-founder of Arcutis Biotherapeutics, as its Chief Innovation Officer. Dr. Osborne has extensive experience in developing topical therapies, including contributions to the development of ZORYVE cream and foam.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.